Safety, tolerability and clinical effects of BC007 (Rovunaptabin) on fatigue and quality of life in patients with post-COVID syndrome (reCOVer): a prospective, exploratory, randomised, placebo-control... Background As recent data suggest an involvement of GPCR-fAAb in PCS pathogenesis, neutralisation of such GPCR-fAAbs by BC007 could improve PCS symptoms. The aim of the reCOVer trial was to investigat...

Erlanger reCOVer Studienergebnisse zu BC007 vorab als Preprint
#TeamVorsicht
#TeamVernunft
#TeamWissenschafft
#Longcovid #Postcovid
#BC007

www.medrxiv.org/content/10.1...